- Home
- DTIL vs IMMX Comparison
DTIL vs IMMX Comparison
Compare DTIL & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTIL
- IMMX
- Stock Information
- Founded
- DTIL 2006
- IMMX 2014
- Country
- DTIL United States
- IMMX United States
- Employees
- DTIL N/A
- IMMX N/A
- Industry
- DTIL Biotechnology: Pharmaceutical Preparations
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- DTIL Health Care
- IMMX Health Care
- Exchange
- DTIL Nasdaq
- IMMX Nasdaq
- Market Cap
- DTIL 51.6M
- IMMX 61.1M
- IPO Year
- DTIL 2019
- IMMX 2021
- Fundamental
- Price
- DTIL $4.49
- IMMX $2.65
- Analyst Decision
- DTIL Strong Buy
- IMMX Strong Buy
- Analyst Count
- DTIL 2
- IMMX 1
- Target Price
- DTIL $47.00
- IMMX $7.00
- AVG Volume (30 Days)
- DTIL 546.0K
- IMMX 137.1K
- Earning Date
- DTIL 07-31-2025
- IMMX 08-11-2025
- Dividend Yield
- DTIL N/A
- IMMX N/A
- EPS Growth
- DTIL N/A
- IMMX N/A
- EPS
- DTIL N/A
- IMMX N/A
- Revenue
- DTIL $51,141,000.00
- IMMX N/A
- Revenue This Year
- DTIL N/A
- IMMX N/A
- Revenue Next Year
- DTIL $30.20
- IMMX N/A
- P/E Ratio
- DTIL N/A
- IMMX N/A
- Revenue Growth
- DTIL N/A
- IMMX N/A
- 52 Week Low
- DTIL $3.61
- IMMX $1.26
- 52 Week High
- DTIL $11.09
- IMMX $3.00
- Technical
- Relative Strength Index (RSI)
- DTIL 54.93
- IMMX 61.44
- Support Level
- DTIL $4.08
- IMMX $2.16
- Resistance Level
- DTIL $4.38
- IMMX $2.80
- Average True Range (ATR)
- DTIL 0.28
- IMMX 0.17
- MACD
- DTIL 0.05
- IMMX 0.04
- Stochastic Oscillator
- DTIL 85.26
- IMMX 80.00
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.